Home

News

What we'd like to tell you about...

Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.

Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.

Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

Medical Diagnostic Laboratories, L.L.C., Announces New Line of Dermatopathology Testing including Melanoma Hereditary Genetics

Medical Diagnostic Laboratories, L.L.C., Announces New Line of Urology Testing including Prostate Cancer and Renal Cancer Hereditary Genetics

Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio

Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

Genesis Biotechnology Group announces second year of CRO relationship with Yale University

Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

Genesis Biotechnology Group Appoints Erich E. Dagnal as Director of Mergers & Acquisitions

Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima

Medical Diagnostic Laboratories, L.L.C., Expands Availability of Coronavirus Disease 2019 (COVID-19) Testing into New York and Increases Testing Capabilities

Medical Diagnostic Laboratories, L.L.C., Launches Serological Test for Coronavirus Disease 2019 (COVID-19) Antibodies in Human Serum.

Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)

Genesis Biotechnology Group® (GBG) Announces First Annual Community Fall Fest in Hamilton

Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma

Medical Diagnostic Laboratories, L.L.C., Fights Tick- and Mosquito-borne Epidemic with New Comprehensive Testing for Vector-borne Disease.

Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

Genesis Biotechnology Group announces partnership with Yale University

Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer

Abstract accepted for Presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting April 29 - May 03, 2018 in Honolulu, Hawaii

Genesis Biotechnology Group® Acquires Assets of 4path, Ltd to Expand their Diagnostic Branch

Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

Mercer County Community College has launched a partnership with GBG to give students the opportunity to work while they learn

Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Test

Mercer Regional Chamber of Commerce 2011 Award

Announcing new testing for Aerobic Vaginitis (AV)

A Complimentary Reflex Test to Determine Metronidazole Resistance in Trichomonas vaginalis.

New Bacterial Vaginosis/Lactobacillus Profiling Assay

New HPV-16 Status Test

Biotech Company Sponsors International Bacterial Vaginosis Symposium to Continue Support of Women's Health

Notice

This link leads to the machine-readable files that are made available to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators and application developers to more easily access and analyze data.